<iframe src="//www.googletagmanager.com/ns.html?id=GTM-MX3DVL" height="0" width="0" style="display:none;visibility:hidden"></iframe>Pestalozzi advised Mylan on its USD 5.3 billion acquisition of part of Abbott Laboratories’ generic drugs business | Pestalozzi Attorneys at Law

Pestalozzi advised Mylan on its USD 5.3 billion acquisition of part of Abbott Laboratories’ generic drugs business

01.07.2014

Mylan Inc. announced that it has entered into a definitive agreement with Abbott Laboratories whereby Mylan Inc. will acquire Abbott Laboratories' non US developed markets specialty and branded generics business in an all-stock transaction. Upon closing, Abbott Laboratories will receive 105 million shares of the combined company worth approximately USD 5.3 billion based on Mylan Inc.’s closing price of USD 50.20 on Friday, 11 July 2014, representing an approximately 21% ownership stake. Pestalozzi represented Mylan Inc. in the Swiss legal aspect of this transaction.

To the top

Cookies

Okay
We use cookies in order to optimally design and continuously improve our website. By continuing to use the website you consent to the use of cookies. For further information about cookies please view our data protection statement.